In the late 1990s, VistaGen
Therapeutics’ founders established the company to make their dreams a reality.
The founders wanted to create human cell-based biological assay systems that
provide reliable insight into the healing and harmful effects of new drug
candidates long before they are ever tested in humans and, now, next-generation
biological assays can provide the type and quality of valuable pre-clinical
human data that will increase the possibility of choosing safer, more effective
therapeutics for clinical development.
VistaGen’s drug rescue
pursuits combine its human pluripotent stem cell technology platform, Human
Clinical Trials in a Test Tube™, with contemporary curative chemistry. By doing
so, the company is able to produce newer, safer chemical variants (drug rescue
variants) of once-promising small molecule drug candidates that were halted in
development by the U.S. National Institutes of Health, pharmaceutical
companies, or university laboratories because of heart or liver toxicity or
metabolism issues. VistaGen uses its stem cell technology to create early
predictions of how humans will eventually respond to the new drug candidates
before they are ever tested in humans, bringing human biology to the start of
the drug development process. Specifically, VistaGen applies its stem cell
technology to drug rescue, predictive toxicology, and drug metabolism
screening.
In the fifteen years since
the California-based biotechnology company was founded, VistaGen has designed
and developed CardioSafe 3D™, a high throughput, human heart cell-based
bioassay. Recently, the company reported significant developments demonstrating
that CardioSafe 3D is a clinically predictive system for the preclinical
cardiac safety screening of anti-cancer drug candidates, including small
molecule kinase inhibitors (KI), a new category of drugs that has transformed
cancer therapy due to its increased target cell efficacy and reduced systemic
toxicity when compared to classic cancer drugs.
The company is also
developing and validating LiverSafe 3D™, a novel, three-dimensional in-vitro
bioassay system for evaluating liver toxicity and drug metabolism issues.
VistaGen also has a small
molecule drug candidate in development: AV-101, an orally available small molecule.
AV-101 has completed Phase 1 development for the treatment of neurological
diseases and disorders, including neuropathic pain, a serious and chronic
condition that causes pain after an injury or disease of the peripheral or
central nervous system and that affects millions of people worldwide.
For more information, visit
www.vistagen.com.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
